BioDlink International Announces Extraordinary General Meeting to Approve Major CDMO Master Services Agreement with WuXi XDC Cayman Inc.
BioDlink International Company Limited (Stock Code: 1875) has issued a Notice of Extraordinary General Meeting (EGM), set for Thursday, 11 June 2026 at 1:00 p.m. The EGM will be conducted in a hybrid format, allowing shareholders to attend both physically at 120 Changyang Street, Suzhou Industrial Park, Suzhou, PRC, and virtually online.
Key Highlights:
- Approval of Significant CDMO Master Services Agreement:
- The EGM will consider and, if thought fit, pass an ordinary resolution to approve, confirm, and ratify the CDMO Master Services Agreement dated 26 May 2026 between BioDlink International and WuXi XDC Cayman Inc.. This agreement and the transactions under it represent a potentially significant development in BioDlink’s CDMO (Contract Development and Manufacturing Organization) business strategy.
- The meeting will also approve the annual caps (i.e., maximum transaction limits) for the agreement for the years ending 31 December 2026, 2027, and 2028.
- If approved, directors or their authorized persons will be empowered to execute all necessary documents and make arrangements to implement the agreement, including minor amendments if needed.
- Shareholder Participation and Voting:
- Shareholders may attend the EGM in person or virtually, and are entitled to appoint one or more proxies to vote on their behalf. Proxies do not have to be members of the Company.
- For joint shareholdings, only the first named shareholder in the register is entitled to vote if more than one joint holder is present.
- Proxy forms must be submitted to Tricor Investor Services Limited or via the online portal by 1:00 p.m. on Tuesday, 9 June 2026.
- The record date for determining eligibility to attend and vote is Thursday, 11 June 2026
- The register of members will be closed for transfers from Tuesday, 9 June 2026 to Thursday, 11 June 2026 (both days inclusive).
- Resolution to be Decided by Poll: The outcome of the EGM will be determined by poll, ensuring transparency and equal voting rights for all shareholders.
- Board Composition: The current board consists of Dr. Jincai Li (Executive Director and Chairperson), Mr. Xiaojie Xi (Non-Executive Director), and three Independent Non-Executive Directors: Mr. Xin Fan, Dr. Ulf Grawunder, and Dr. Chaohong Hu.
Potential Price-Sensitive Implications for Investors:
- The approval of the CDMO Master Services Agreement with WuXi XDC Cayman Inc. could represent a material development for BioDlink International, potentially impacting future revenue streams and business scope.
- Such agreements with leading industry players like WuXi XDC are often viewed positively by the market, as they may provide stable and potentially significant business opportunities over multiple years.
- Investors should note the annual transaction caps for 2026, 2027, and 2028, as these set the upper limits of the business volume that can be conducted under the agreement.
- Shareholders unable to attend the meeting in person are strongly encouraged to participate virtually and exercise their voting rights, as the outcome may influence the company’s strategic direction and future performance.
Instructions for Shareholders:
- Check your eligibility to vote by ensuring your shares are registered by Monday, 8 June 2026 (before 4:30 p.m.).
- If you wish to appoint a proxy, submit the required documents by the deadline.
- For online participation, use the credentials provided in the notification letter sent by the Company.
This EGM and the resolution regarding the WuXi XDC agreement are potentially significant events for BioDlink International and its shareholders, potentially moving the share price depending on the market’s perception of the agreement’s strategic value.
Disclaimer: This article is for informational purposes only and should not be interpreted as investment advice. Investors are advised to conduct their own research and consult with professional advisors before making any investment decisions. The company and the author assume no responsibility for any actions taken based on this information.
百德連國際召開股東特別大會 審批與無錫藥明生物CDMO主服務協議
百德連國際有限公司（股份代號：1875）發出股東特別大會（EGM）通告，將於2026年6月11日（星期四）下午1時以實體及網上混合方式舉行。股東可親臨蘇州工業園區滄陽街120號會場，或線上出席。
重點摘要：
- 審批重大CDMO主服務協議：
- 大會將審議及（如認為合適）通過一項普通決議案，批准、確認及追認於2026年5月26日與無錫藥明生物技術（開曼）有限公司簽訂的CDMO主服務協議及其所涉交易。該協議意味著百德連國際在CDMO（合同開發與生產組織）業務策略上的重要佈局。
- 會議將同時審批2026、2027及2028年度協議的年度上限（即交易金額最高限額）。
- 如獲通過，董事會或經授權人士可執行有關文件，及對協議作出非重大修訂等安排。
- 股東參與及投票安排：
- 股東可親身或線上出席，並可委任一人或多人成為代理人。代理人無須為公司成員。
- 如股份屬聯名持有，而多於一位持有人出席，則以股東名冊上列名首位者有權行使投票。
- 委託書須於2026年6月9日（星期二）下午1時前交至卓佳證券登記有限公司或指定網站。
- 股東名冊將於2026年6月9日至6月11日期間關閉，屆時暫停辦理股份過戶。
- 持股登記截止時間為2026年6月8日（星期一）下午4:30。
- 決議案以投票形式決定，確保公平公正。
- 董事會現有成員： 執行董事及主席李金才博士、非執行董事奚曉傑先生，獨立非執行董事范鑫先生、Ulf Grawunder博士及胡朝洪博士。
對投資者及股價潛在影響：
- 通過與無錫藥明生物CDMO主服務協議，可能成為公司業務發展的重大利好，有助穩定未來收益並擴大業務規模。
- 與行業龍頭企業合作，市場通常視為正面，有望為公司帶來長期穩定的收入及增長機會。
- 投資者需留意協議的年度交易額上限，作為未來營運規模的參考。
- 未能到場的股東，建議透過網上平台積極參與投票，因結果或對公司策略及未來表現產生重大影響。
股東注意事項：
- 請於2026年6月8日（星期一）下午4:30前完成股份登記。
- 如欲委託代理人，請於限期前提交有關文件。
- 線上參與請使用公司通知函上的賬號及密碼。
是次特別大會及決議案對百德連國際及其股東具重大潛在影響，市場或會因協議內容及戰略價值而調整公司股價。
免責聲明： 本文僅供參考，並不構成任何投資建議。投資者應自行研究及諮詢專業人士後作出投資決定。公司及作者對據此信息而採取的行動不承擔任何責任。
